上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
MP7 (Synonyms: PDK1 inhibitor) 纯度: 99.83%
MP7 (PDK1 inhibitor) 是一种磷酸肌醇依赖性激酶-1 (PDK1) 抑制剂。
MP7 Chemical Structure
CAS No. : 1001409-50-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1406 | In-stock | |
5 mg | ¥1237 | In-stock | |
10 mg | ¥2288 | In-stock | |
50 mg | ¥8602 | In-stock | |
100 mg | ¥13020 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
MP7 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- PI3K/Akt/mTOR Compound Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Oxygen Sensing Compound Library
- Glycolysis Compound Library
- Cytoskeleton Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Glucose Metabolism Compound Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor. |
IC50 & Target |
PDK1[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 (PDK1 inhibitor) are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC50 values in the micromolar range[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
516.50 |
||||||||||||||||
Formula |
C28H22F2N4O4 |
||||||||||||||||
CAS 号 |
1001409-50-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 100 mg/mL (193.61 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
The human GBM cells (i.e., U87MG, U343MG, or ANGM-CSS) or the respective GSCs are seeded and incubated for the indicated times with the indicated concentrations of SA16 (1 nM to 100 μM), MP7 (2.5 nM, 25 nM, 250 nM and 2.5 μM), or Alisertib. When indicated, cells are treated with MP7 and Alisertib in combination. To verify GSC chemoresistance, U87MG or GSCs are incubated with 50 μM TMZ for 72 h. For the long-term treatment of cells, NSC or complete medium containing drugs is replaced every 3 days. Cell proliferation is determined using the MTS assay: the dehydrogenase activity in active mitochondria reduces MTS to the soluble formazan product, whose absorbance at 490 nm is measured with an automated plate reader. The mean background from each test condition is subtracted, and the data are expressed as the percentage of untreated cells (control). IC50 values are derived from the sigmoid dose-response curve. The percentage of inhibition is calculated as 100% minus the percentage of cell proliferation[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务